产品中心Cell Resources
联系我们CONTACT US
400-999-210024小时服务热线
![NIH:OVCAR-3 [OVCAR3] (人卵巢癌细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0178-1.jpg)
![NIH:OVCAR-3 [OVCAR3] (人卵巢癌细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0178-2.jpg)
![NIH:OVCAR-3 [OVCAR3] (人卵巢癌细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0178-3.jpg)
![NIH:OVCAR-3 [OVCAR3] (人卵巢癌细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0178-4.jpg)
![NIH:OVCAR-3 [OVCAR3] (人卵巢癌细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0178-5.jpg)
![NIH:OVCAR-3 [OVCAR3] (人卵巢癌细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0178-6.jpg)
![NIH:OVCAR-3 [OVCAR3] (人卵巢癌细胞) (STR鉴定正确)](/Public/upfile/pic/product/cell-line-new.jpg)
![NIH:OVCAR-3 [OVCAR3] (人卵巢癌细胞) (STR鉴定正确)](http://www.procell.com.cn/Public/upfile/pic/xbx/CL-0178-1.jpg)
![NIH:OVCAR-3 [OVCAR3] (人卵巢癌细胞) (STR鉴定正确)](http://www.procell.com.cn/Public/upfile/pic/xbx/CL-0178-2.jpg)
![NIH:OVCAR-3 [OVCAR3] (人卵巢癌细胞) (STR鉴定正确)](http://www.procell.com.cn/Public/upfile/pic/xbx/CL-0178-3.jpg)
![NIH:OVCAR-3 [OVCAR3] (人卵巢癌细胞) (STR鉴定正确)](http://www.procell.com.cn/Public/upfile/pic/xbx/CL-0178-4.jpg)
![NIH:OVCAR-3 [OVCAR3] (人卵巢癌细胞) (STR鉴定正确)](http://www.procell.com.cn/Public/upfile/pic/xbx/CL-0178-5.jpg)
![NIH:OVCAR-3 [OVCAR3] (人卵巢癌细胞) (STR鉴定正确)](http://www.procell.com.cn/Public/upfile/pic/xbx/CL-0178-6.jpg)
![NIH:OVCAR-3 [OVCAR3] (人卵巢癌细胞) (STR鉴定正确)](http://www.procell.com.cn/Public/upfile/pic/product/cell-line-new.jpg)
产品概述
| 名称 | NIH:OVCAR-3 [OVCAR3] (人卵巢癌细胞) (STR鉴定正确) |
| 别称 | Ovcar-3; NIH:OVCAR-3; NIH:Ovcar-3; NIH:OVCAR3; NIH-OVCAR-3; NIHOVCAR3; OVCAR.3; OVCAR3; Ovcar3 |
| 背景描述 | NIH:OVCAR-3 [OVCAR3]细胞是由T·C·Hamilton在1982年建系，NIH:OVCAR-3 [OVCAR3]细胞取材于患进行性卵巢腺癌病人的恶性腹水。NIH:OVCAR-3 [OVCAR3]细胞与107细胞联合皮下接种5只裸鼠21天后全部成瘤。NIH:OVCAR-3 [OVCAR3]细胞是研究卵巢癌药物抗性的一个合适的模型系统且由于存在激素受体，这对于激素治疗的评估或许是有用的。 |
| 种属 | 人 |
| 年龄（性别） | 女；60岁 |
| 组织来源 | 卵巢腺癌 |
| 生长特性 | 贴壁细胞 |
| 细胞形态 | 上皮细胞样 |
| 细胞类型 | 肿瘤细胞 |
| 肿瘤类型 | 卵巢癌细胞 |
| 生物安全等级 | 1 |
| 生长培养基 | RPMI-1640＋20% FBS＋0.01mg/ml Insulin＋1% P/S |
| 推荐传代比例 | 1:2-1:4 |
| 推荐换液频率 | 2~3次/周 |
| 倍增时间 | ~35-64 hours |
| 冻存条件 | 冻存液：55% 基础培养基+40%FBS+5%DMSO 温度：液氮 |
| 培养条件 | 气相：空气，95%；CO2，5% 温度：37℃ |
| 致瘤性 | Yes, Forms colonies in soft agar. Yes, in nude mice inoculated subcutaneously with 1×10^7 cells (Tumors developed within 21 days at 100% frequency (5/5)). |
| 受体表达情况 | Androgen receptor, positive; estrogen receptor, positive; progesterone receptor, positive |
| 保藏机构 | ATCC; HTB-161 |
STR鉴定
-
STR位点信息
Amelogenin X CSF1PO 11,12 D2S1338 17,21 D3S1358 17,18 D5S818 11,12 D7S820 10 D8S1179 10,15 D13S317 12 D16S539 12 D18S51 13 D19S433 14,16.2 D21S11 29,31.2 FGA 21 PentaD 12,13 PentaE 7,13 TH01 9 TPOX 8 vWA 17 D6S1043 10,11 D12S391 19,22 D2S441 11,14 -
STR鉴定图
-
参考文献
-
A 19F NMR probe for the detection of β-galactosidase: simple structure with low molecular weight of 274.2, “turn-on” signal without the background, and good performance applicable in cancer cell line(2017/06/28)
作者：Jie Hu, Qiong Wu, Kai Cheng
期刊：J Mater Chem B
影响因子 ：7.571
引用产品：CL-0178
-
Isothiocyanate Iberin inhibits cell proliferation and induces cell apoptosis in the progression of ovarian cancer by mediating ROS accumulation and GPX1 expression(2021/06/17)
作者：Tingting Gong, Qian Guo, Xiao Li
期刊：Biomedicine & Pharmacotherapy
DOI：10.1016/j.biopha.2021.111533
影响因子 ：7.419
-
CircLNPEP promotes the progression of ovarian cancer through regulating miR-876-3p/ WNT5A axis(2021/08/31)
作者：Wenwen Wang, Weiwei Zhang, Hongjun Guo
期刊：Cell Cycle
DOI：10.1080/15384101.2021.1965723
影响因子 ：5.173
-
miR‑638 suppresses proliferation by negatively regulating high mobility group A1 in ovarian cancer cells(2021/9/20)
作者：Li Ma, Wei Zhang, Yaofeng Jin
期刊：Experimental and Therapeutic Medicine
影响因子 ：2.7510
